Commentary examines barriers to continuous glucose monitoring adoption, suggesting integrated strategies for improvement.
Continuous glucose monitoring (CGM) improves glycemic control and reduces acute events, yet adoption remains low despite expanded coverage. Real-world evidence shows that most eligible patients do not use CGMs, highlighting a gap between access and utilization. This commentary examines key barriers, including provider knowledge gaps, administrative complexity, workflow constraints, and persistent socioeconomic inequities. We argue that coverage expansion alone is insufficient to drive uptake. Coordinated strategies that support prescriber education, streamline processes, and integrate CGM into routine care are needed. Addressing these systemic and behavioral barriers is essential to realizing the full clinical and economic benefits of CGM at scale.
No takes yet. Share an insight, caveat, or question.
Dennis et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: